Canaccord Genuity raises Hinge Health price target to $76
Canaccord Genuity analyst Richard Close maintained a Buy rating on Hinge Health (NYSE: HNGE) and raised the price target to $76 from $65. The adjustment signals increased confidence in the digital health company's valuation potential.
*this image is generated using AI for illustrative purposes only.
Canaccord Genuity analyst Richard Close has maintained a Buy rating on Hinge Health (NYSE: HNGE) while raising the price target to $76 from $65. The adjustment reflects increased confidence in the company's valuation potential following recent market performance.
The revised target suggests an upside from current trading levels, reinforcing the analyst's positive stance on the digital health clinic's growth trajectory. Hinge Health operates in the musculoskeletal care sector, a market segment that has seen significant investor interest.
Rating and Price Action
The decision to upgrade the price target comes alongside a reaffirmation of the Buy recommendation. Key financial metrics associated with this rating update are detailed below.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $65 |
| New Price Target | $76 |
The new target of $76 represents a specific valuation benchmark set by Canaccord Genuity for the digital health provider. Investors will monitor Hinge Health's quarterly results to gauge progress toward this revised goal.
What specific growth drivers or market conditions does Canaccord Genuity expect will push Hinge Health's stock to the new $76 target?
How might increased investor interest in the musculoskeletal care sector impact Hinge Health's competitive positioning?
What upcoming quarterly results or milestones should investors watch to gauge progress toward the revised price target?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
